Buy UR-144 Powder (TMCP-018, KM-X1, MN-001, YX-17) is a drug invented by Abbott Laboratories, that acts as a selective full agonist of the peripheral cannabinoid receptor CB2, but with much lower affinity for the psychoactive CB1 receptor.

Pharmacology
UR-144 has high affinity for the CB2 receptor with a Ki of 1.8 nM but 83x lower affinity for the CB1 receptor with a Ki of 150 nM. It was found to possess an EC50 of 421 nM for human CB1 receptors, and 72 nM for human CB2 receptors. UR-144 produces bradycardia and hypothermia in rats at a dose of 10 mg/kg, suggesting weak cannabinoid-like activity.

Chemically it is closely related to other 2,2,3,3-tetramethylcyclopropyl synthetic cannabinoids like A-796,260 and A-834,735 but with a different substitution on the 1-position of the indole core, in these compounds its 1-pentyl group is replaced with alkylheterocycles like 1-(2-morpholinoethyl) and 1-(tetrahydropyran-4-ylmethyl).

Chemical and physical data
Formula: C21H29NO

Molar mass: 311.461 g/mol g·mol?1

Dose
Inhalation (tentative due to a lack of information)

Range: 2.5 to 20 mg
Most people have been exposed to the drug in the form of blends that contain varying levels of UR-144. Its not wise to use those products.

Timeline
Inhalation (tentative due to a lack of information)
Total: 1 2 hours
Onset: Under 10 minutes
See also
AB-001
AM-1221
4-HTMPIPO
FAB-144
JTE 7-31
JWH-018
N-(S)-Fenchyl-1-(2-morpholinoethyl)-7-methoxyindole-3-carboxamide
XLR-11
Tetramethylcyclopropylfentanyl